EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

EGFR and HER2 hyper-activation mediates resistance to endocrine therapy and CDK4/6 inhibitors in ER+ breast cancer

Stefania Belli, Daniela Esposito, Claudia M Ascione, Francesca Messina, Fabiana Napolitano, Alberto Servetto, Carmine De Angelis, Roberto Bianco, Luigi Formisano

Cancer Letters · 2024-07 · 593 · 216968

DOI: 10.1016/j.canlet.2024.216968 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Letters, 2024-07. Verfasst von Stefania Belli und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Medicine and Surgery, University of Naples "Federico II", 80131 Naples, Italy. Electronic address: stefania.bell21@gmail.com. Hauptthemen laut MEDLINE: Breast Neoplasms, Erb-b2 Receptor Tyrosine Kinases, Drug Resistance, Neoplasm, Cyclin-Dependent Kinase 4. Die Arbeit wurde bisher 36-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In patients with ER + metastatic breast cancer (mBC), the first-line treatment involves the combination of endocrine therapy (ET) and CDK4/6 inhibitors (CDK4/6i). However, a significant group of patients experiences disease progression, emphasizing the urgent clinical need to identify novel anti-tumor therapies. We previously generated breast cancer cells resistant to the combination of fulvestrant (ER downregulator) and abemaciclib (CDK4/6 inhibitor) from MCF7 and T47D (MCF7-FAR and T47D-FAR). RNA-seq-based Gene Set Enrichment Analysis (GSEA) revealed hyper-activation of EGFR, HER2, and AKT signaling in both MCF7-FAR and T47D-FAR. Modulating EGFR or ERBB2 expression through loss- and gain-of-function experiments altered tumor sensitivity to fulvestrant and abemaciclib in parental and FAR spheroids, affecting ERK and AKT/S6 pathways. Cetuximab treatment overcame tumor resistance to fulvestrant and abemaciclib in FAR and EGFR-overexpressing breast cancer spheroids and xenografts. Likewise, patient-derived organoids (PDOs) from individuals with ER + mBC, progressing on palbociclib, exhibited up-regulation of EGFR and HER2 pathways. In conclusion, our findings suggest that inhibiting EGFR and HER2 pathways might overcome resistance to ET + CDK4/6i in selected patients with ER + mBC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsErb-b2 Receptor Tyrosine KinasesDrug Resistance, NeoplasmCyclin-Dependent Kinase 4ErbB ReceptorsCyclin-Dependent Kinase 6Receptors, EstrogenHumansFemaleAnimalsMiceFulvestrantProtein Kinase InhibitorsBenzimidazolesAminopyridinesXenograft Model Antitumor AssaysAntineoplastic Agents, HormonalMCF-7 CellsCell Line, TumorAntineoplastic Combined Chemotherapy Protocols

Stichwörter der Autor:innen

CDK4/6 inhibitorsDrug resistanceER+ breast cancerEndocrine therapyErbB family

Substanzen

Erb-b2 Receptor Tyrosine KinasesCyclin-Dependent Kinase 4ErbB ReceptorsCyclin-Dependent Kinase 6Receptors, EstrogenFulvestrantProtein Kinase InhibitorsBenzimidazolesAminopyridinesAntineoplastic Agents, Hormonal

Autor:innen und Institutionen

  • Department of Clinical Medicine and Surgery, University of Naples "Federico II", 80131 Naples, Italy. Electronic address: stefania.bell21@gmail.com.
  • Department of Clinical Medicine and Surgery, University of Naples "Federico II", 80131 Naples, Italy. Electronic address: daniela.esposito1989@gmail.com.
  • Department of Clinical Medicine and Surgery, University of Naples "Federico II", 80131 Naples, Italy. Electronic address: claudia97ascione@gmail.com.
  • Department of Clinical Medicine and Surgery, University of Naples "Federico II", 80131 Naples, Italy. Electronic address: francescamessina507@gmail.com.
  • Department of Clinical Medicine and Surgery, University of Naples "Federico II", 80131 Naples, Italy. Electronic address: fabi.napolitano@gmail.com.
  • Department of Clinical Medicine and Surgery, University of Naples "Federico II", 80131 Naples, Italy. Electronic address: alberto.servetto@unina.it.

Zitieren

APA

Belli, S., Esposito, D., Ascione, C. M., Messina, F., Napolitano, F., Servetto, A., De Angelis, C., Bianco, R., & Formisano, L. (2024). EGFR and HER2 hyper-activation mediates resistance to endocrine therapy and CDK4/6 inhibitors in ER+ breast cancer. Cancer Letters, 593, 216968. https://doi.org/10.1016/j.canlet.2024.216968

Vancouver

Belli S, Esposito D, Ascione CM, Messina F, Napolitano F, Servetto A, et al. EGFR and HER2 hyper-activation mediates resistance to endocrine therapy and CDK4/6 inhibitors in ER+ breast cancer. Cancer Letters. 2024;593:216968. doi:10.1016/j.canlet.2024.216968

BibTeX
@article{Belli2024,
  author = {Belli, Stefania and Esposito, Daniela and Ascione, Claudia M and Messina, Francesca and Napolitano, Fabiana and Servetto, Alberto and De Angelis, Carmine and Bianco, Roberto and Formisano, Luigi},
  title = {EGFR and HER2 hyper-activation mediates resistance to endocrine therapy and CDK4/6 inhibitors in ER+ breast cancer},
  journal = {Cancer Letters},
  year = {2024},
  volume = {593},
  pages = {216968},
  doi = {10.1016/j.canlet.2024.216968}
}
Kostenlos starten →